YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Allarity Therapeutics, Inc. TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a…
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Allarity Therapeutics, Inc. (ALLR) one of those stocks right now? Let's take a closer look at the sto…
Principal Investigator Kathleen N. Moore, M.D., a leading expert in advanced ovarian cancer, will present the poster TARPON SPRINGS, Fla., June 18, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Price swings ahead of the opening bell are being driven by clinical trial and regulatory updates, as well as trial endpoint misses. In the Green - Premar…
* Allarity Therapeutics press release [https://seekingalpha.com/pr/20517811-allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenoparib-development] (ALLR [https://seekingalpha.com/symbol/ALLR]): Q1 GAAP EPS of -$0.17…
(RTTNews) - Allarity Therapeutics, Inc. (ALLR), a clinical-stage biopharma focused on personalized cancer treatments, announced it has closed a $20 million non-convertible debt financing with Streeterville Capital to accelerate the develop…
Allarity (ALLR) Therapeutics closed a $20 million non-convertible debt financing with Streeterville Capital. The transaction is structured as a note purchase agreement pursuant to which the Company issued two non-convertible promissory not…
Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible Debt Financi…
TARPON SPRINGS, Fla., December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and…
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trial Advanced DRP® platform through new licensing agreement TARPON SPRINGS,…
* Allarity Therapeutics (NASDAQ:ALLR [https://seekingalpha.com/symbol/ALLR]) prospectus covers up to 1.56M shares of common stock offered by a selling stockholder. * Shares consist of: 760,916 common shares, and 801,584 shares issuable upo…
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now mor…
TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pat…
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? By taking a look at the stock's year-to-date performance in compa…
Unusual volume stocks are being observed in Wednesday's session. [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT INHD [https://www.chartmill.com/stock/quote/INHD/profile] 31.57% INNO HOLDINGS INC (NASDAQ:INHD [https://www.c…
Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index rising 0.6% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 90.28% INVIVYD INC'S (NASDAQ:IVVD [http…
Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today. [mostactive] TOP MOST ACTIVE STOCKS TICKER CHANGE COMMENT IXHL [https://www.chartmill.com/stock/quote/IXHL/profile]…
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT NUKKW [https://www.chartmill.com/st…
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Allarity Therapeutics Inc. 196,807,150 2.28 1.75 1.84 +0.8987 Incannex Hea…
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT HKPD [https://www.chartmill.com/stock/quote/HKP…
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witnessed a remarkable su…
TARPON SPRINGS, Fla. - Allarity Therapeutics, Inc. (NASDAQ:ALLR), a small-cap biotech company with a market capitalization of $14.45 million, announced Tuesday that the U.S. Food and Drug Administration has granted Fast Track designation t…
Allarity Therapeutics, Inc. TARPON SPRINGS, Fla., August 26, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentia…
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial - Expanded global IP protection by securing Australian patent acceptance for the stenoparib DRP® companion diagnostic - Secured new service contract with EU biote…
Investing.com - Ascendiant Capital initiated coverage on Allarity Therapeutics Inc . (NASDAQ:ALLR) with a Buy rating and a $9.00 price target on Monday, adding to the growing interest in the biotechnology sector. The clinical-stage biophar…
TARPON SPRINGS, Fla., July 15, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
* Allarity Therapeutics (NASDAQ:ALLR [https://seekingalpha.com/symbol/ALLR]) announced on Monday the appointment of Jeff Ervin as the company’s new chief financial officer (CFO). * Ervin succeeds Alexander Epshinsky, who will remain engage…
TARPON SPRINGS, Fla., July 7, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
TARPON SPRINGS, Fla., June 27, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
TARPON SPRINGS, Fla., June 11, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
TARPON SPRINGS, Fla., June 2, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway…
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash and restricted cash b…
Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities into 2027 Strengthened cash position expected to support the Company through first substantive data reado…